Get the lowdown on the differences between prostate cancer care: Canada v. United States

Researcher to explain all at BC meeting

(Celestia “Tia” Higano, MD)

February 1, 7-8 p.m. Pacific time. Above and below the 49th parallel.

Are active surveillance and other prostate cancer topics identical on either side of the U.S.-Canada border? Inquiring minds want to know.

Celestia “Tia”  Higano, MD, who has cared for patients on both sides of the border, will tell all in a webinar sponsored by Vancouver-based Tri-Cities Prostate Cancer Support and Awareness Group in Vancouver, British Columbia.

Her program is entitled "Prostate Cancer Research, Education and Treatment Across Two Sides of the Border.”

Join the Zoom meeting: https://us02web.zoom.us/j/85938513944?pwd=c01kcysvcE80TFdaa0x1UTRTZS9LZz09

Higano was formerly a professor in the Departments of Medicine and Urology, Division of Medical Oncology at the University of Washington, and the Clinical Division of Fred Hutchison Cancer Research Center. She is an Adjunct Professor in the Department of Urologic Sciences at the University of British Columbia. She has been the Medical Director of the Prostate Cancer Supportive Care Program at the Vancouver Prostate Centre since 2013.

Higano received her medical degree from the University of Massachusetts Medical School and completed her residency at the Mayo Graduate School of Medicine in Rochester, Minnesota. She was an oncology fellow at the Fred Hutchison Cancer Research Center and the University of Washington. Higano is an internationally renowned expert and clinical researcher focusing on prostate cancer. At UW, she led the prostate cancer clinical research group that participated in developing agents such as zoledronic acid, sipuleucel-T, enzalutamide, apalutamide, abiraterone, and radium 223.

Meanwhile, do you keep your cancer secret? Please answer TheActiveSurveillor Quick Survey.